surmount-2 tirzepatide type 2 diabetes weight loss results 2023 2024 reduction with different doses of in Surmount 1 New Blockbuster Type 2 Medication

Must stop medication and seek urgent care

A disproportionality analysis (Godfrey et al., JEADV 2025) found a reporting odds ratio of 1.73 for tirzepatide (95% CI: 1.42 to 2.09), and as high as 2.46 for semaglutide

But it is especially important to pair microdosing with lifestyle modifications, because the lower receptor activation at sub-therapeutic doses means you are relying more on behavioral changes to drive results during the early weeks

NAION isnt the only eye problem showing up in people taking GLP-1 drugs

Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial